Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | President, R&D | June 17, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,613 |
Ending reported balance
After 2024-06-17 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-06-17 · Exercise / conversion · Acquired 1,404 · Balance 68,017 Row 2 · 2024-06-17 · Exercise / conversion · Acquired 12,500 · Balance 80,517 Row 3 · 2024-06-17 · Sale · Disposed 12,500 · Balance 68,017 Row 4 · 2024-06-17 · Sale · Disposed 1,404 · Balance 66,613 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2033-03-07 | Direct | 46,324 |
Reported balance
After 2024-06-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-17 · Exercise / conversion · Disposed 1,404 · Balance 46,324 F1: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09 · Expires 2033-03-27 | Direct | 37,500 |
Reported balance
After 2024-06-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-06-17 · Exercise / conversion · Disposed 12,500 · Balance 37,500 F1: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2024 Filed Jun 20, 2024 21:08 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $6.09 Strike: $6.09 | $76,125.00 |
DisclosureSEC source: 0001593968-24-000879 · primary_01.xml · derivative · entry 6 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires 2033-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:08 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,404 | $6.97 Strike: $6.97 | $9,785.88 |
DisclosureSEC source: 0001593968-24-000879 · primary_01.xml · derivative · entry 5 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,324 Underlying: Common Stock · 1,404 shares Expires 2033-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:08 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,404 | $14.54 | $20,414.16 |
DisclosureSEC source: 0001593968-24-000879 · primary_01.xml · nonDerivative · entry 4 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,613 Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:08 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 12,500 | $14.46 | $180,750.00 |
DisclosureSEC source: 0001593968-24-000879 · primary_01.xml · nonDerivative · entry 3 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,017 Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:08 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 12,500 | $6.09 | $76,125.00 |
DisclosureSEC source: 0001593968-24-000879 · primary_01.xml · nonDerivative · entry 2 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:08 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,404 | $6.97 | $9,785.88 |
DisclosureSEC source: 0001593968-24-000879 · primary_01.xml · nonDerivative · entry 1 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 16, 2024 01:15 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,652 | $0.00 Strike: $6.97 | $0.00 |
DisclosureSEC source: 0001104659-24-062148 · tm2414680-1_4seq1.xml · derivative · entry 3 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,728 Underlying: Common Stock · 19,652 shares Expires 2033-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the March 7, 2023 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| May 14, 2024 Filed May 16, 2024 01:15 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 47,312 | $13.90 | $657,636.80 |
DisclosureSEC source: 0001104659-24-062148 · tm2414680-1_4seq1.xml · nonDerivative · entry 2 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,953 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $14.00, inclusive. The Reporting Person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 14, 2024 Filed May 16, 2024 01:15 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 19,652 | $6.97 | $136,974.44 |
DisclosureSEC source: 0001104659-24-062148 · tm2414680-1_4seq1.xml · nonDerivative · entry 1 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 5,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-033620 · tm248710-2_4seq1.xml · derivative · entry 3 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,376 Underlying: Common Stock · 5,376 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,597 | $5.45 | $14,153.65 |
DisclosureSEC source: 0001104659-24-033620 · tm248710-2_4seq1.xml · nonDerivative · entry 2 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,613 Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 5,376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-033620 · tm248710-2_4seq1.xml · nonDerivative · entry 1 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 19,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-033165 · tm248549-3_4seq1.xml · derivative · entry 3 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 9,392 | $5.61 | $52,689.12 |
DisclosureSEC source: 0001104659-24-033165 · tm248549-3_4seq1.xml · nonDerivative · entry 2 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,834 Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 19,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-033165 · tm248549-3_4seq1.xml · nonDerivative · entry 1 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 01, 2024 Filed Mar 26, 2024 23:00 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 144,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-039163 · tm249879-2_4seq1.xml · derivative · entry 1 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058982 · doc4.xml · derivative · entry 3 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Plan vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment with the Company through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Plan vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,368 | $5.69 | $7,783.92 |
DisclosureSEC source: 0001209191-23-058982 · doc4.xml · nonDerivative · entry 2 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,782 Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 2,833 | $5.69 | $16,119.77 |
DisclosureSEC source: 0001209191-23-058982 · doc4.xml · nonDerivative · entry 1 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2023 Filed Nov 7, 2023 22:30 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054625 · doc4.xml · derivative · entry 3 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the November 5, 2020 grant date, in each case subject to continued employment with the Company through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the November 5, 2020 grant date, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| November 05, 2023 Filed Nov 7, 2023 22:30 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 677 | $7.06 | $4,779.62 |
DisclosureSEC source: 0001209191-23-054625 · doc4.xml · nonDerivative · entry 2 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,317 Read SEC document |
| November 05, 2023 Filed Nov 7, 2023 22:30 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,400 | $7.06 | $9,884.00 |
DisclosureSEC source: 0001209191-23-054625 · doc4.xml · nonDerivative · entry 1 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). Read SEC document |
| September 16, 2023 Filed Sep 19, 2023 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 12,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050009 · doc4.xml · derivative · entry 3 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,644 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-half (1/2) of the RSUs on each of the first two (2) anniversaries of the September 16, 2021 grant date, in each case subject to continued employment with the Company through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-half (1/2) of the RSUs on each of the first two (2) anniversaries of the September 16, 2021 grant date, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| September 16, 2023 Filed Sep 19, 2023 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 6,108 | $7.71 | $47,092.68 |
DisclosureSEC source: 0001209191-23-050009 · doc4.xml · nonDerivative · entry 2 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,594 Read SEC document |
| September 16, 2023 Filed Sep 19, 2023 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 12,644 | $7.71 | $97,485.24 |
DisclosureSEC source: 0001209191-23-050009 · doc4.xml · nonDerivative · entry 1 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 4,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038804 · doc4.xml · derivative · entry 3 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 16, 2020 grant date, in each case subject to continued employment with the Company through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 16, 2020 grant date, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,007 | $8.04 | $16,136.28 |
DisclosureSEC source: 0001209191-23-038804 · doc4.xml · nonDerivative · entry 2 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,058 Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,155 | $8.04 | $33,406.20 |
DisclosureSEC source: 0001209191-23-038804 · doc4.xml · nonDerivative · entry 1 Dubovsky Filip · CIK 0001977361 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.